Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TOP: Tysabri® Observational Program

Trial Profile

TOP: Tysabri® Observational Program

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Jan 2019

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational
  • Acronyms TOP
  • Sponsors Biogen
  • Most Recent Events

    • 02 Jan 2019 Planned number of patients changed from 6000 to 4500.
    • 12 Oct 2018 Interim results (n=6149 , data cut off Nov 2017) presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 12 Oct 2018 Results (n=6149 , data cut off Nov 2017) examining relapses resulting in hospitalization or steroid use in RRMS patients in TOP , presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top